These are the stocks posting the largest moves before the bell.Market Insiderread more
The Federal Reserve's expected interest rate cuts appears to have impacted J.P. Morgan's forecast for 2019 net interest income.Financeread more
Credit card sales volume rose 11% this quarter and merchant processing volume increased 12%, the bank says in its earnings statement.Banksread more
Current and former Tesla employees working in the company's open-air "tent" factory say they felt pressure to take shortcuts to hit aggressive Model 3 production goals,...Technologyread more
KeyCorp said in an 8-K filing the fraud involves a "business customer" and was discovered "on or about" July 9.Banksread more
GE hasn't had a year this good during this millennium. After that massive surge, one trader is warning investors to stay away.Trading Nationread more
Domino's Pizza stock fell Tuesday after reporting disappointing sales, despite beating Wall Street's earnings estimates.Restaurantsread more
CNBC Make It set out to find the schools that provide middle-class American students the highest average salaries for their tuition dollars.Definitive Guide to Collegeread more
U.S. retail sales increased more than expected in June, pointing to strong consumer spending.Economyread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
The Food and Drug Administration has issued a warning to genetics testing company 23andMe to immediately halt sales of its Saliva Collection Kit and Personal Genome Service (PGS).
In a letter, the FDA said the DNA-testing products were being sold without "marketing clearance or approval" in violation of the Food, Drug and Cosmetic Act.
"FDA is concerned about the public health consequences of inaccurate results from the PGS device; the main purpose of compliance with FDA's regulatory requirements is to ensure that the tests work," the agency said.
(Read more: Backlash by the bay: Tech riches alter a city)
According to 23andMe's website, the saliva kit can determine details about the user's health, including susceptibility to certain diseases, as well as about ancestry.
"We recognize that we have not met the FDA's expectations regarding timeline and communication regarding our submission," 23andMe said in a statement. "Our relationship with the FDA is extremely important to us, and we are committed to fully engaging with them to address their concerns."
Anne Wojcicki, who recently separated from Google co-founder Sergey Brin, co-founded 23andMe in 2006. Google is an investor in the company.
(Read more: Google mulled ditching US after NSA scandal)
Since 2010, the FDA has required that all services claiming to evaluate a user's risk of disease must be approved by U.S. regulators for direct-to-consumer sales.
—By CNBC's Karma Allen